Thyrocare Technologies Ltd (THYROCARE) — Corporate Action | 21 September 2026

Thyrocare Technologies announced on September 21, 2026, that its board approved the sale of its entire 100% stake in wholly owned subsidiary Nueclear Healthcare Limited (NHL) to Trovera Healthcare Private Limited for approximately [amount not verified]. The consideration comprises 42,500 compulsorily convertible preference shares (CCPS) in Trovera issued at a premium of ₹13,990 per share (totaling [amount not verified]) and cash of [amount not verified], subject to working capital adjustments. The transaction, valued by V.B. Desai Financial Services, requires shareholder approval and is expected to close by November 30, 2026. Concurrently, the company approved purchasing immovable properties in Gurugram and Hyderabad from NHL for [amount not verified]. The sale enables Thyrocare to exit the radiology business and focus on its core pathology operations.